Publications by authors named "Oosterhuis W"

Objectives: Adequate analytical quality of reported results is primarily ensured by performing internal quality control (iQC). Currently, several different iQC practices are in use. As a prelude to the revision of a Dutch guidance document on analytical QC, a questionnaire was sent out to gain insights in the applied practices and the need for guidance.

View Article and Find Full Text PDF
Article Synopsis
  • The EU Diagnostic Device Regulation (IVDR) emphasizes risk-based validation, traceability, and post-market monitoring of diagnostic devices while excluding medical services based on these devices.
  • Laboratory-developed tests (LDTs) can be used when commercial devices are unavailable, subjecting them to specific performance and safety guidelines under an ISO 15189-equivalent quality system.
  • The IVDR may lead to the disappearance of some commercial tests, necessitating urgent LDT replacements, while raising concerns about the potential loss of niche medical applications and increased costs within healthcare systems.
View Article and Find Full Text PDF

When increasing the quality in clinical laboratories by decreasing measurement uncertainty, reliable methods are needed not only to quantify the performance of measuring systems, but also to set goals for the performance. Sigma metrics used in medical laboratories for documenting and expressing levels of performance, are evidently totally dependent on the "total permissible error" used in the formulas. Although the conventional biological variation (BV) based model for calculation of the permissible (or allowable) total error is commonly used, it has been shown to be flawed.

View Article and Find Full Text PDF

Uncertainty is an inseparable part of all kinds of measurements performed in clinical laboratories. Accreditation standards including the ISO/IEC 17025:2017 and ISO 15189:2012 require that laboratories have routines for calculating the measurement uncertainty of reported results. Various guidelines such as CLSI EP29, Nordest 537, and ISO 20914:2019 have proposed methods for this purpose.

View Article and Find Full Text PDF

Background: Elevated levels of Chromogranin A (CgA) may be indicative of a neuroendocrine tumour (NET), but increased levels are also observed after intake of proton pump inhibitors (PPIs). The incidence of diagnostic confusion because of this drug-laboratory test interaction (DLTI) was examined.

Methods: Medical records of 238 patients with elevated CgA concentrations were obtained from three hospitals.

View Article and Find Full Text PDF

Objectives: For the correct interpretation of test results, it is important to be aware of drug-laboratory test interactions (DLTIs). If DLTIs are not taken into account by clinicians, erroneous interpretation of test results may lead to a delayed or incorrect diagnosis, unnecessary diagnostic testing or therapy with possible harm for patients. A DLTI alert accompanying a laboratory test result could be a solution.

View Article and Find Full Text PDF

A 26-year-old woman, who underwent abdominal surgery because of pelvic endometriosis, suffered from upper abdominal pain, fever and dyspnoea 2 days postoperatively. Paralytic ileus and right-sided pneumothorax were revealed. Treatment with a chest drain was not successful and, thus, a video-assisted thoracoscopic surgery was performed, revealing endometriosis-like lesions.

View Article and Find Full Text PDF
Article Synopsis
  • Knowledge of drug-laboratory test interactions (DLTIs) is essential for accurate lab test interpretation, as overlooking these interactions can lead to misdiagnosis or unnecessary treatments.
  • A multicenter survey involving 210 physicians assessed their awareness of DLTIs using six clinical case scenarios, focusing on their desire for alerts and how these might affect their decision-making.
  • Results showed that 93% of doctors favored receiving DLTIs, noting that such alerts influenced their medical decisions in various cases, indicating that alerts should cater to the specific needs of physicians.
View Article and Find Full Text PDF

Objectives: There are many mobile health applications (apps) now available and some that use in some way laboratory medicine data. Among them, patient-oriented are of the lowest content quality. The aim of this study was to compare the opinions of non-laboratory medicine professionals (NLMP) with those of laboratory medicine specialists (LMS) and define the benchmarks for quality assessment of laboratory medicine apps.

View Article and Find Full Text PDF

The in vitro diagnostic medical devices regulation (IVDR) will take effect in May 2022. This regulation has a large impact on both the manufacturers of in vitro diagnostic medical devices (IVD) and clinical laboratories. For clinical laboratories, the IVDR poses restrictions on the use of laboratory developed tests (LDTs).

View Article and Find Full Text PDF

Background: Reflective testing, i.e. interpreting, commenting on and, if necessary, adding tests in order to aid the diagnostic process in a meaningful and efficient manner, is an extra service provided by laboratory medicine.

View Article and Find Full Text PDF

Uncertainty is an inseparable part of all types of measurement. Recently, the International Organization for Standardization (ISO) released a new standard (ISO 20914) on how to calculate measurement uncertainty (MU) in laboratory medicine. This standard can be regarded as the beginning of a new era in laboratory medicine.

View Article and Find Full Text PDF

Vascular invasion has been identified as an informative risk factor for relapse in stage I testicular nonseminomas, used to tailor treatment. We investigated interobserver agreement in vascular invasion reporting and studied the potential additional value of immunohistochemistry for vascular markers for predicting relapse. Patients (n=52) with stage I testicular nonseminomas undergoing surveillance (1993-2006) were included (median follow-up of 66 mo).

View Article and Find Full Text PDF

Background Knowledge of possible drug-laboratory test interactions (DLTIs) is important for the interpretation of laboratory test results. Test results may be affected by physiological or analytical drug effects. Failure to recognize these interactions may lead to misinterpretation of test results, a delayed or erroneous diagnosis or unnecessary extra tests or therapy, which may harm patients.

View Article and Find Full Text PDF

In laboratory medicine, consultation by adding interpretative comments to reports has long been recognized as one of the activities that help to improve patient treatment outcomes and strengthen the position of our profession. Interpretation and understanding of laboratory test results might in some cases considerably be enhanced by adding test when considered appropriate by the laboratory specialist - an activity that was named reflective testing. With patient material available at this stage, this might considerably improve the diagnostic efficiency.

View Article and Find Full Text PDF

Intake of drugs may influence the interpretation of laboratory test results. Knowledge and correct interpretation of possible drug-laboratory test interactions (DLTIs) is important for physicians, pharmacists and laboratory specialists. Laboratory results may be affected by analytical or physiological effects of medication.

View Article and Find Full Text PDF

Reliable procedures are needed to quantify the performance of instruments and methods in order to increase the quality in clinical laboratories. The Sigma metrics serves that purpose, and in the present study, the current methods for the calculation of the Sigma metrics are critically evaluated. Although the conventional model based on permissible (or allowable) total error is widely used, it has been shown to be flawed.

View Article and Find Full Text PDF

Analytical performance specifications are crucial in test development and quality control. Although consensus has been reached on the use of biological variation to derive these specifications, no consensus has been reached which model should be preferred. The Six Sigma concept is widely applied in industry for quality specifications of products and can well be compared with Six Sigma models in clinical chemistry.

View Article and Find Full Text PDF
Article Synopsis
  • The role of clinical pathologists is being challenged by advancements in technology, patient autonomy in requesting tests, and the use of non-medical specialists.
  • Clinical pathologists are responding by focusing on the pre-analytical and postanalytical phases of Laboratory Medicine, which allows for better interpretation of complex lab results.
  • The paper emphasizes the importance of the Medical Act in maintaining high standards in Laboratory Medicine and advocates for enhanced training programs to ensure quality care.
View Article and Find Full Text PDF

Measurements in clinical laboratories produce results needed in the diagnosis and monitoring of patients. These results are always characterized by some uncertainty. What quality is needed and what measurement errors can be tolerated without jeopardizing patient safety should therefore be defined and specified for each analyte having clinical use.

View Article and Find Full Text PDF

Error methods - compared with uncertainty methods - offer simpler, more intuitive and practical procedures for calculating measurement uncertainty and conducting quality assurance in laboratory medicine. However, uncertainty methods are preferred in other fields of science as reflected by the guide to the expression of uncertainty in measurement. When laboratory results are used for supporting medical diagnoses, the total uncertainty consists only partially of analytical variation.

View Article and Find Full Text PDF

Background: There is increasing interest in direct patient engagement including receiving their laboratory medicine results. We previously established an appetite for Specialists in Laboratory Medicine to support patients in understanding results. The aim of this study was to establish whether patients agreed with such an approach, determined through surveying views in eight European countries.

View Article and Find Full Text PDF

Background: The primary aim of the study was to investigate prognosis and long-term survival in young breast cancer patients with a BRCA1 or BRCA2 germline mutation compared with noncarriers. The secondary aim was to investigate whether differences in survival originate from associations with tumor characteristics, second cancers, and/or treatment response.

Methods: We established a cohort of invasive breast cancer patients diagnosed younger than age 50 years in 10 Dutch hospitals between 1970 and 2003.

View Article and Find Full Text PDF